Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Incyte, a Delaware-based drug discovery and development company focused on developing proprietary small molecule drugs for oncology and inflammation, has appointed Wendy Dixon, former chief marketing officer and president of global marketing at Bristol-Myers Squibb Company (BMS), to its board of directors.
Subscribe to our email newsletter
Dr Dixon’s prior experience include 30 years in the biopharmaceutical industry involving multiple product launches and new drug approvals across a broad range of therapeutic areas and the establishment of commercial organisations in the US and Europe.
She was also involved in the effective integration of R&D, clinical, marketing, manufacturing and regulatory programs to achieve development of competitive new products.
Paul Friedman, president and CEO of Incyte, said: “Dr Dixon’s technical background, combined with direct experience in building marketing and sales teams and commercialising new pharmaceutical products, will be of great value as we prepare for the potential launch of our first product.
“Her involvement in all aspects of drug development, including the prioritisation of product portfolios, will also be important as we work to maximise the value of Incyte’s broad maturing pipeline for our key stakeholders.”